20 NOVEMBRE 2020
Urine Cytology Market Information: By Product (Urine Cytology Instrument, Urine Cytology Kit), By Indication (Urinary Infection, Inflammatory Disease, Cancer), By End User (Hospitals & Clinics, Diagnostic Centers, Home Care) - Global Forecast till 2023
Urine cytology examination is used as a diagnostic measure in the diagnosis of cancer and urinary tract infection. This test is one of the most important diagnostic tools for the patients with unexplained blood in the urine, burning during urination, and pain during urination.
The healthcare provider may recommend urine cytology examination if the patient has symptoms such as unexplained blood in the urine, burning and pain during urination. It is commonly used for the diagnosis of infection, inflammatory disease of the urinary tract, cancer of kidney, bladder, ureter, urethra, and others.
Major Players in Urine Cytology Market
Some of the key players in the global market are
- ThermoFischer Scientific (U.S.)
- BD (U.S.)
- Sigma- Aldrich (U.S.)
- Severn Biotech Limited (U.K)
- Bio-Techne (U.S.)
- Laboratory Corporation of America Holdings (U.S.)
- Hoffmann-La Roche Ltd (Switzerland)
- and others.
Urine Cytology Market Segmentation
The global urine cytology market is segmented on the basis of Product, Indication, And End User.
On the basis of product, market is segmented into urine cytology instrument, urine cytology kit, and others. Product is further segmented into automated, and manual instrument.
On the basis of indication, the market is segmented into urinary infection, inflammatory disease, cancer, and others. Cancer is further segmented into kidney, bladder, ureter, and urethra.
On the basis of end user, the market is segmented into hospitals & clinics, diagnostic centers, home care, and others.
Urine Cytology Market Regional Analysis
In the Americas, rising prevalence of various types of allergies, arthritis, tendinitis, and others, and rising demand for corticosteroid injection in the U.S. are key driver for the growth of the market.
Europe is the second largest market for urine cytology owing to the rising prevalence of cancer in European countries and availability of funds for research and development activities.
The market in Asia Pacific is expected to grow at the fastest pace and is driven increasing healthcare expenditure, and China, and India are the leading countries with increasing prevalence of infectious diseases.
The Middle East & Africa also show a steady rise in the market owing to high prevalence of chronic diseases, and increasing healthcare expenditure also influences the market growth in the Middle East & African countries.
Brows Complete Premium Research Report Enabled with Respective Table and Figures at https://www.marketresearchfuture.com/reports/urine-cytology-market-5116
About Market Research Future:
we enable our customers to unravel the complexity of various industries through our Cooked Research Report (CRR), Half-Cooked Research Reports (HCRR), Raw Research Reports (3R), Continuous-Feed Research (CFR), and Market Research & Consulting Services
The global next generation sequencing market expected to reach US$ 25.85 billion by 2028 according to a new study by Polaris Market Research.
The report “Next Generation Sequencing (NGS) Market Share, Size, Trends, Industry Analysis Report, By Application (Drug Discovery/Personalized Medicine, Genetic Screening, Diagnostics/Infectious Diseases, Agricultural & Animal Research); By Technology; By Product; By End-Use; By Regions; Segment Forecast, 2021 – 2028” gives a detailed insight into current market dynamics and provides analysis on future market growth.
Market players are focusing on developing automated sequencers equipped with high speed and accuracy.
This has also enabled increased adoption in emerging nations.
The global next-generation sequencing market is fragmented based on application, technology, product, end-use, and region.
In terms of application, the market is segmented into drug discovery/personalized medicine, genetic screening, diagnostics/infectious diseases, agricultural & animal research, and others.
The research report includes specific segments by region (country), by company, by Type and by Application.
This study provides information about the sales and revenue during the historic and forecasted period of 2016 to 2027.
Understanding the segments helps in identifying the importance of different factors that aid the market growth.
Segment by TypeDownload FREE Sample of this Report @ https://www.grandresearchstore.com/report-sample/global-orphan-drugs-2021-520 OncologyGastrointestinalPulmonaryNeurologyHematologyCardio-vascularMetabolic disordersEndocrinologyInfectious diseasesOthers Segment by Application Hospital PharmaciesSpeciality PharmaciesRetail pharmaciesOthers By Region North AmericaU.S.CanadaEuropeGermanyFranceU.K.ItalyRussiaAsia-PacificChinaJapanSouth KoreaIndiaAustraliaTaiwanIndonesiaThailandMalaysiaPhilippinesVietnamLatin AmericaMexicoBrazilArgentinaMiddle East & AfricaTurkeySaudi ArabiaU.A.E By Company Novartis AGBristol-Myers Squibb CompanyCelgene CorporationF.
Hoffmann-La Roche Ltd.Pfizer, Inc.Sanofi S.A.Alexion Pharmaceuticals, Inc.Eli Lilly and CompanyNovo Nordisk A/SAstraZenecaEisai Co., Ltd.Daiichi Sankyo Company LimitedBayer AGGlaxoSmithKlineMerck & Co., Inc.Johnson & JohnsonBiogen, Inc.TakedaAmgen, Inc.Get the Complete Report & TOC @ https://www.grandresearchstore.com/life-sciences/global-orphan-drugs-2021-520Table of content1 Orphan Drugs Market Overview1.1 Product Overview and Scope of Orphan Drugs1.2 Orphan Drugs Segment by Type1.2.1 Global Orphan Drugs Sales Growth Rate Comparison by Type (2021-2027)1.2.2 Oncology1.2.3 Gastrointestinal1.2.4 Pulmonary1.2.5 Neurology1.2.6 Hematology1.2.7 Cardio-vascular1.2.8 Metabolic disorders1.2.9 Endocrinology1.2.10 Infectious diseases1.2.11 Others1.3 Orphan Drugs Segment by Application1.3.1 Orphan Drugs Sales Comparison by Application: (2021-2027)1.3.2 Hospital Pharmacies1.3.3 Speciality Pharmacies1.3.4 Retail pharmacies1.3.5 Others1.4 Global Orphan Drugs Market Size Estimates and Forecasts1.4.1 Global Orphan Drugs Revenue 2016-20271.4.2 Global Orphan Drugs Sales 2016-20271.4.3 Orphan Drugs Market Size by Region: 2016 Versus 2021 Versus 20272 Orphan Drugs Market Competition by Manufacturers2.1 Global Orphan Drugs Sales Market Share by Manufacturers (2016-2021)2.2 Global Orphan Drugs Revenue Market Share by Manufacturers (2016-2021)2.3 Global Orphan Drugs Average Price by Manufacturers (2016-2021)2.4 Manufacturers Orphan Drugs Manufacturing Sites, Area Served, Product Type2.5 Orphan Drugs Market Competitive Situation and Trends2.5.1 Orphan Drugs Market Concentration Rate2.5.2 The Global Top 5 anCONTACT US:276 5th Avenue, New York , NY 10001,United StatesInternational: (+1) 646 781 7170 / +91 8087042414Follow Us On linkedin :- https://www.linkedin.com/company/grand-research-store/
At an estimated value of over 27.49 billion USD in 2019, the global Beta-lactam and Beta-lactamase Inhibitors Market is predicted to thrive at a CAGR of 1.9% and valued at over USD 34.20 billion over the forecast year 2020-2030.Beta-lactam inhibitors fall under a class of antibiotics that consists of all antibiotic agents that have a beta lactam ring embedded in their molecular structure.
These antibiotic agents helps fight against bacterial infections and protozoa infections.
On the basis of disease, the market is segmented into Urinary Tract Infection (excluding cUTI), Respiratory Infection, Skin Infection, Complicated Urinary Tract Infection (cUTI), Complicated Intra-Abdominal Infections (cIAI), Nosocomial Pneumonia, Blood Stream Infection and others.
In terms of geography, the market is categorized into North America, Europe, Asia Pacific and RoW.Request sample copy of this report at:- https://www.nextmsc.com/beta-lactam-beta-lactamase-inhibitors-market/request-sample The North America region is anticipated to hold the major market share as a result of advanced health care facilities and infrastructure in conjunction with rise in acceptance of beta-lactam and beta-lactamase inhibitors.
The Asia Pacific region is predicted to show rapid and consistent growth in market share within the forecast period.
This region also indicates increased prevalence of infectious diseases in addition to rise in consumption of such drugs, which also serves as favorable factor for the beta-lactam and beta-lactamase inhibitor market.About Next Move Strategy Consulting:Next Move Strategy Consulting is an independent and trusted third-platform market intelligence provider, committed to deliver high quality, market research reports that help multinational companies to triumph over their competitions and increase industry footprint by capturing greater market share.
Anti-Viral Drugs Market OverviewGlobal anti-viral drugs market is expected to grow at a CAGR of 6.9% and attain USD 62.67 Bn by the end of the forecast period of 2016-2022, asserts Market Research Future (MRFR) in an exhaustive research report.
Infectious diseases such as influenza, herpes, hepatitis C are among the leading causes of death worldwide.
The incidence rate of HIV has seen a surge in recent years, especially in the developing countries which indicate high demand for anti-viral drugs.
The paucity of new anti-viral drugs will be addressed by this drug development which will eliminate the reliance on the limited number of drugs.
Besides, growing focus on R activities provides ample opportunities for market growth.
Anti-Viral Drugs Market Regional AnalysisThe Americas, Europe, Asia Pacific, and Middle East & Africa are the key markets for antiviral drugs.
The global infectious disease diagnostics market was valued at USD 13.93 Billion in 2016 and projected to reach USD 19.35 Billion in 2022, at a CAGR of 5.6%.
The base year considered for the study is 2016, and the forecast for the market size is provided for the period between 2017 and 2022.
Growth in this market is primarily driven by the increasing global prevalence of infectious diseases, shift in focus from centralized laboratories to decentralized point-of-care testing, and growth in funding for research on infectious disease diagnosticsDownload PDF Brochure: https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=116764589Global Market Segmentation:The market is broadly segmented into assays, kits, & reagents; instruments; and services & software based on product & service.
The assays, kits, & reagents segment accounted for the largest share of the global market and is expected to register the highest CAGR during the forecast period.
The increasing number of infectious disease diagnostic tests carried out; easy accessibility to a wide range of reagents; and the growing need for reliable, specific, and faster detection of infectious diseases in the early stages are the key factors driving the IDD assays, kits, & reagents market.Based on the disease type, the market is segmented into hepatitis, HIV, HAIs, CT/NG, HPV, TB, Influenza, and other diseases.
The hepatitis diagnostics segment accounted for the largest share of the global market in 2017.
New York, NY 13 May 2021: The global next generation sequencing market expected to reach US$ 25.85 billion by 2028 according to a new study by Polaris Market Research.
The report “Next Generation Sequencing (NGS) Market Share, Size, Trends, Industry Analysis Report, By Application (Drug Discovery/Personalized Medicine, Genetic Screening, Diagnostics/Infectious Diseases, Agricultural & Animal Research); By Technology; By Product; By End-Use; By Regions; Segment Forecast, 2021 – 2028” gives a detailed insight into current market dynamics and provides analysis on future market growth.
Market players are focusing on developing automated sequencers equipped with high speed and accuracy.
This has also enabled increased adoption in emerging nations.
In terms of application, the market is segmented into drug discovery/personalized medicine, genetic screening, diagnostics/infectious diseases, agricultural & animal research, and others.
Request For Sample Copy @ https://www.polarismarketresearch.com/industry-analysis/next-generation-sequencing-ngs-market/request-for-sample Segment HighlightsInfectious diseases segment is estimated to hold a major share in the global next generation sequencing market, owing to increasing usage of NGS in infectious diseases.
